Achieving robust and scalable AAV empty/full capsid separation for gene therapy

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Achieving robust and scalable AAV empty/full capsid separation for gene therapy

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

AAV vectors have become one of the leading platforms for gene therapy delivery. The inherent formation of empty AAV capsids during upstream production poses a challenge for drug developers, as empty AAV capsids lack the DNA payload and have no therapeutic benefit. Anion exchange chromatography (AEX) using membranes or resins has become a popular tool for the separation of empty and full capsids.

It is crucial that tools used to achieve empty/full AAV capsid separation provide effective, repeatable, and scalable separation. In many cases, the AEX operating space is narrow, and the reliability on processing equipment and reagents is critical. Therefore, having reproducible batches of AEX membranes or resins is necessary.

In this webinar, membrane reproducibility will be presented across three different manufacturing batches utilizing three different AAV5 feedstreams. Data will be shown demonstrating repeatability via rapidly cycling the membrane, which provides consistent performance and also opens up the possibility of reducing the size of the device at the manufacturing scale.

Attend this webinar to learn about:

How AEX utilizing membranes and resins can be used for separation of empty and full capsids
Why reproducibility across manufacturing batches is crucial to enable a robust empty and full AAV capsid separation solution
Case studies demonstrating highly repeatable results, providing a pathway to process large amounts of AAV feedstream by cycling

Mark Schofield

Senior R&D Manager at Cytiva

Mark Schofield earned his degrees in Scotland, he received his bachelor’s degree from the University of Edinburgh and his molecular biology Ph.D from the University of Dundee. For the last 12 years he has been an employee of Pall and now Cytiva focusing on chromatography applications. Currently he holds the position of Senior R&D manager, his team works on bioprocess intensification solutions and chromatographic separations for gene therapy modalities.

Julio Huato

R&D Engineer II at Cytiva

Julio Huato Hernandez is a bioprocess R&D engineer at Cytiva. He holds a bachelor’s degree in chemical engineering from Northeastern University. He has been working at Cytiva for 5 years centering on viral vector and mAb downstream applications. His work has a focus on membrane based separations.